The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain. While symptoms can now be better managed with lifelong treatment, there is ...

This story is part of our series on viroids and virusoids, small infectious RNAs. The story is also the second installment in a series on hepatitis D virus, a virusoid-like pathogen that causes ...

On the left is integrase in its “intasome” structure of four identical four-part complexes (pink) that connect to create one 16-part complex that locks around viral DNA (blue). On the right is ...

A new antiretroviral target has been identified that suppresses HIV-1 replication and selectively kills HIV-1-infected cells. HIV-1 is the most common type of HIV. When HIV-1 leaves infected cells, ...

Prevention remains critical; but once symptoms appear, treatment options are extremely limited. Because rabies hides behind a complex molecular shield, it is nearly impossible to fight. “For more than ...

The FDA granted priority review, with a decision expected by June 19, 2025. LEN represents a novel class of HIV therapies by targeting the viral capsid, a multifunctional protein essential for HIV ...